Vancomycin pharmacokinetics and pharmacodynamics during short daily hemodialysis

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 11, 2010, Pages 1981-1987

  Decker, Brian S ^a   Kays, Michael B ^a,b   Chambers, Mary ^a   Kraus, Michael A ^a   Moe, Sharon M ^a   Sowinski, Kevin M ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ADULT; ANTIBIOTIC PROPHYLAXIS; ANURIA; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG HALF LIFE; FEMALE; HEMODIALYSIS; HUMAN; LOADING DRUG DOSE; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; SHORT DAILY HEMODIALYSIS;

ADULT; ANTI-BACTERIAL AGENTS; ANURIA; AREA UNDER CURVE; COMPUTER SIMULATION; DRUG DOSAGE CALCULATIONS; FEMALE; HUMANS; INDIANA; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MODELS, BIOLOGICAL; MONTE CARLO METHOD; RENAL DIALYSIS; VANCOMYCIN;

EID: 78149306096     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03450410     Document Type: Article

References (39)

1. US Renal Data System: USRDS 2009 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2009
2. Pierratos A: Daily (quotidian) nocturnal home hemodialysis: Nine years later. Hemodial Int 8: 45-50, 2004
3. Vos PF, Zilch O, Kooistra MP: Clinical outcome of daily dialysis. Am J Kidney Dis 37: S99-S102, 2001
4. Pierratos A: Daily hemodialysis: An update. Curr Opin Nephrol Hypertens 11: 165-171, 2002
5. Nissenson AR: Daily hemodialysis: Challenges and opportunities in the delivery and financing of end-stage renal disease patient care. Adv Ren Replace Ther 8: 286-292, 2001
6. Ayus JC, Mizani MR, Achinger SG, Thadhani R, Go AS, Lee S: Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: A prospective, controlled study. J Am Soc Nephrol 16: 2778-2788, 2005
7. Pierratos A, McFarlane P, Chan CT: Quotidian dialysis: Update 2005. Curr Opin Nephrol Hypertens 14: 119-124, 2005
8. D'Agata EM: Antimicrobial-resistant, Gram-positive bacteria among patients undergoing chronic hemodialysis. Clin Infect Dis 35: 1212-1218, 2002 (Pubitemid 35305869)
9. Martins Castro MC, Luders C, Elias RM, Abensur H, Romao Junior JE: High-efficiency short daily haemodialysis: Morbidity and mortality rate in a long-term study. Nephrol Dial Transplant 21: 2232-2238, 2006
10. McFarlane PA: More of the same: Improving outcomes through intensive hemodialysis. Semin Dial 22: 598-602, 2009
11. Punal Rioboo J, Sanchez-Iriso E, Ruano-Ravina A, Varela Lema ML, Sanchez-Guisande D, Gonzalez-Rodriguez L, Herrero JA, Barril G, Maduell F, Hernandez J, Otero A, Bajo MA, Sanchez R: Short daily versus conventional hemodialysis quality of life: A cross-sectional multicentric study in Spain. Blood Purif 28: 159-164, 2009
12. Klevens RM, Edwards JR, Andrus ML, Peterson KD, Dudeck MA, Horan TC: Dialysis surveillance report: National Healthcare Safety Network (NHSN) - Data summary for 2006. Semin Dial 21: 24-28, 2008
13. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK: NHSN annual update: Antimicrobial- resistant pathogens associated with healthcare-associated infections - Annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 29: 996-1011, 2008
14. Pai AB, Pai MP: Optimizing antimicrobial therapy for gram-positive bloodstream infections in patients on hemodialysis. Adv Chronic Kidney Dis 13: 259-270, 2006
15. Fridkin SK: Vancomycin-intermediate and -resistant Staphylococcus aureus: What the infectious disease specialist needs to know. Clin Infect Dis 32: 108-115, 2001
16. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb Mortal Wkly Rep 51: 565-567, 2002
17. Liu C, Chambers HF: Staphylococcus aureus with heterogeneous resistance to vancomycin: Epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 47: 3040-3045, 2003
18. Moore MR, Perdreau-Remington F, Chambers HF: Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob Agents Chemother 47: 1262-1266, 2003
19. Howden BP, Johnson PD, Ward PB, Stinear TP, Davies JK: Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 50: 3039-3047, 2006
20. Launay-Vacher V, Izzedine H, Mercadal L, Deray G: Clinical review: Use of vancomycin in haemodialysis patients. Crit Care 6: 313-316, 2002 (Pubitemid 34863697)
21. Pai AB, Pai MP: Vancomycin dosing in high flux hemodialysis: A limited-sampling algorithm. Am J Health Syst Pharm 61: 1812-1816, 2004
22. Ariano RE, Fine A, Sitar DS, Rexrode S, Zelenitsky SA: Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis. Am J Kidney Dis 46: 681-687, 2005
23. Pallotta KE, Manley HJ: Vancomycin use in patients requiring hemodialysis: A literature review. Semin Dial 21: 63-70, 2008
24. Sakoulas G, Gold HS, Cohen RA, Venkataraman L, Moellering RC, Eliopoulos GM: Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother 57: 699-704, 2006
25. Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P, Grabsch EA, Roberts SA, Robson J, Read K, Bak N, Hurley J, Johnson PD, Morris AJ, Mayall BC, Grayson ML: Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 38: 521-528, 2004
26. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC Jr, Craig WA, Billeter M, Dalovisio JR, Levine DP: Therapeutic monitoring of vancomycin in adults: Summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy 29: 12751279, 2009
27. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP: Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66: 82-98, 2009
28. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ: Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 43: 925-942, 2004
29. Lucksiri A, Scott MK, Mueller BA, Hamburger RJ, Sowinski KM: CAHP-210 dialyzer influence on intra-dialytic vancomycin removal. Nephrol Dial Transplant 17: 1649-1654, 2002
30. D'Argenio DZ, Schumitzky A: ADAPT 5, User's Guide: Pharmacokinetic and Pharmacodynamic Systems Analysis Software, Los Angeles, Biomedical Simulations Resource, University of Southern California, 2009
31. Leypoldt JK, Jaber BL, Zimmerman DL: Predicting treatment dose for novel therapies using urea standard Kt/V. Semin Dial 17: 142-145, 2004
32. Prakash V, Lewis JS 2nd, Jorgensen JH: Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob Agents Chemother 52: 4528, 2008
33. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, Alamo D, Ortega M, Lopez J, Mensa J: Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 46: 193-200, 2008 (Pubitemid 351269157)
34. Barth RH, DeVincenzo N: Use of vancomycin in high-flux hemodialysis: Experience with 130 courses of therapy. Kidney Int 50: 929-936, 1996
35. Maclayton DO, Suda KJ, Coval KA, York CB, Garey KW: Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin Ther 28: 1208-1216, 2006
36. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM: Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42: 2398-2402, 2004
37. Moise PA, Sakoulas G, Forrest A, Schentag JJ: Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 51: 2582-2586, 2007
38. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A: High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: Efficacy and toxicity. Arch Intern Med 166: 2138-2144, 2006
39. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, Stellrecht K: Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 52: 3315-3320, 2008